Skip to main
AGEN
AGEN logo

Agenus (AGEN) Stock Forecast & Price Target

Agenus (AGEN) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 22%
Hold 22%
Sell 0%
Strong Sell 0%

Bulls say

Agenus Inc has demonstrated a positive financial performance, reporting collaboration revenue of $26.8 million for 4Q24, an increase from $25.1 million in the previous quarter, highlighting its ability to generate consistent revenue growth. The company is executing strategic cost reductions, projecting a 60% decrease in annual external expenditures for 2025, which suggests improved operational efficiency and financial health. Furthermore, encouraging clinical activity has been observed, particularly for its antibody candidates, with high rates of partial responses in ongoing trials, strengthening the company's position in the competitive biopharmaceutical landscape.

Bears say

Agenus Inc. reported operating expenses of $28.7 million, reflecting a roughly 50% decline from the previous quarter, significantly exceeding prior estimates. The financial outlook remains negative due to several inherent risks, including potential safety issues in clinical programs, efficacy falling short of expectations, and substantial competition in the oncology space, alongside an anticipated need for approximately $300 million to $700 million in additional financing through 2037. Moreover, the company's shift towards investigator-sponsored trials and the need for a large Phase 3 trial for its lead candidates may further delay approval and necessitate significant capital investment, compounding the challenges facing its financial stability.

Agenus (AGEN) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 22% recommend Buy, 22% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Agenus and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Agenus (AGEN) Forecast

Analysts have given Agenus (AGEN) a Buy based on their latest research and market trends.

According to 9 analysts, Agenus (AGEN) has a Buy consensus rating as of Jul 12, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.81, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.81, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Agenus (AGEN)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.